Literature DB >> 17846854

Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients.

Karl Y Bilimoria1, James S Tomlinson, Ryan P Merkow, Andrew K Stewart, Clifford Y Ko, Mark S Talamonti, David J Bentrem.   

Abstract

The natural history of pancreatic neuroendocrine tumors (PNET) remains poorly defined. Our objectives were to examine the clinicopathologic features of PNETs, to assess treatment trends over time, and to identify factors associated with undergoing resection. From the National Cancer Data Base (1985-2004), 9,821 patients were identified with PNETs. Clinicopathologic features and treatment trends were examined. Multivariable logistic regression was used to assess factors associated with undergoing resection. Of 9,821 patients with PNETs, 85% were nonfunctional, 7.1% were functional, and 7.9% were carcinoid tumors. Of the 3,851 (39.0%) patients who underwent pancreatectomy, 449 (11.7%) received adjuvant chemotherapy, and 254 (6.6%) received adjuvant radiation. From 1985 to 2004, utilization of pancreatectomy increased from 39.4 to 44.3% (P < 0.0001). Patients were less likely to undergo resection if they were > 55 years old, had tumors in the head of the pancreas, tumors > or = 4 cm, or had distant metastases (P < 0.0001). Patients treated at NCCN/NCI, academic, or high-volume hospitals were more likely to undergo resection. There are disparities in the utilization of pancreatectomy for PNETs. As PNETs have a better prognosis than adenocarcinoma, concerns regarding the morbidity and mortality of pancreatic surgery and neoplasms should not preclude resection.

Entities:  

Mesh:

Year:  2007        PMID: 17846854     DOI: 10.1007/s11605-007-0263-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  30 in total

1.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

2.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  An evaluation of radical surgery for carcinoma of the pancreas and ampullary region.

Authors:  A O WHIPPLE
Journal:  Ann Intern Med       Date:  1949-10       Impact factor: 25.391

Review 4.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Endocrine pancreatic tumors: factors correlated with survival.

Authors:  P Tomassetti; D Campana; L Piscitelli; R Casadei; D Santini; F Nori; A M Morselli-Labate; R Pezzilli; R Corinaldesi
Journal:  Ann Oncol       Date:  2005-08-05       Impact factor: 32.976

6.  Malignant nonfunctioning endocrine tumors of the pancreas: predictive factors for survival after surgical treatment.

Authors:  Jun Chul Chung; Dong Wook Choi; Sung Ho Jo; Jin Seok Heo; Seong Ho Choi; Yong Il Kim
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

7.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

8.  Islet cell carcinoma of the pancreas. A study of 98 patients.

Authors:  S Venkatesh; N G Ordonez; J Ajani; P N Schultz; R C Hickey; D A Johnston; N A Samaan
Journal:  Cancer       Date:  1990-01-15       Impact factor: 6.860

9.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

10.  Pancreaticoduodenectomy: a 20-year experience in 516 patients.

Authors:  C Max Schmidt; Emilie S Powell; Constantin T Yiannoutsos; Thomas J Howard; Eric A Wiebke; Chad A Wiesenauer; Joel A Baumgardner; Oscar W Cummings; Lewis E Jacobson; Thomas A Broadie; David F Canal; Robert J Goulet; Eardie A Curie; Higinia Cardenes; John M Watkins; Patrick J Loehrer; Keith D Lillemoe; James A Madura
Journal:  Arch Surg       Date:  2004-07
View more
  52 in total

1.  Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.

Authors:  Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

2.  Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Amit Tirosh; Sanjit Mukherjee; Justin Lack; Sudheer Kumar Gara; Sophie Wang; Martha M Quezado; Xavier M Keutgen; Xiaolin Wu; Maggie Cam; Suresh Kumar; Dhaval Patel; Naris Nilubol; Monica Varun Tyagi; Electron Kebebew
Journal:  Cancer       Date:  2019-01-08       Impact factor: 6.860

Review 3.  Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia.

Authors:  Ajay V Maker; Raashid Sheikh; Vinita Bhagia
Journal:  Langenbecks Arch Surg       Date:  2017-07-21       Impact factor: 3.445

4.  Pancreatic neuroendocrine tumor with cystlike changes: evaluation with MDCT.

Authors:  Satomi Kawamoto; Pamela T Johnson; Chanjuan Shi; Aatur D Singhi; Ralph H Hruban; Christopher L Wolfgang; Barish H Edil; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

5.  Tumor registry versus physician medical record review: a direct comparison of patients with pancreatic neuroendocrine tumors.

Authors:  Elisabet E Manasanch; Jillian K Smith; Andreea Bodnari; Jeannine McKinney; Catherine Gray; Theodore P McDade; Jennifer F Tseng
Journal:  J Oncol Pract       Date:  2011-03       Impact factor: 3.840

6.  Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Sanziana Roman; Shelby Reed; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-05-20       Impact factor: 5.344

Review 7.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

8.  Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Authors:  Marianne E Pavel; Alexandria T Phan; Edward M Wolin; Beloo Mirakhur; Nilani Liyanage; Susan Pitman Lowenthal; George A Fisher; Aaron I Vinik
Journal:  Oncologist       Date:  2018-10-24

9.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

Review 10.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.